Weight loss was accompanied by improvements in cardiometabolic parameters, including a decrease in systolic blood pressure (-9.9 mmHg) and waist circumference (-17.5 cm) (placebo-adjusted: 6.7 mmHg and 13.5 cm, respectively)
"As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine
How to Prevent Contamination Keeping the process sterile is critical
Its honestly the best Skin Renewal clinic in town
Figure 4 Correlations When the data from both groups where pooled together, the change in specific mitochondrial respiration activating complex I and II correlated positively with changes in serum testosterone concentrations ( r = 0.46, p = 0.006), and free androgen index ( r = 0.43, p = 0.01)